Skin Reactions with Losartan and Enalapril in Cardiac Patients

Document Type : Original Article(s)

Authors

1 Professor, Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, Skin Diseases and Leishmaniasis Research Center And Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

5 Associate Professor, Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Numerous reports have been published about the skin reaction after using angiotensin II converting enzyme inhibitors (ACEIs) such as enalapril and angiotensin II receptor blockers (ARBs) such as losartan. However, no such investigations have been conducted to evaluate skin complications after ACEIs and ARBs intake. According to racial differences in reaction to medications and high rate prescription of theses mentioned drugs, we aimed to design the present study.Methods: This cross-sectional study was performed on hospitalized or referred patients who were taking losartan or enalapril in University Hospitals of the Isfahan University of Medical Sciences in 2008. 200 patients were randomly enrolled to the study.Findings: Skin reactions developed in 4.5% of the participants (4.5% in losartan and 5% in enalapril users). The most common skin complications were urticaria, maculopapular rashes and angioedema. The average time from taking the medication to the development of skin complications was 6.1 months, which appeared between 1-2 months from drug prescription in 88.8% of the cases. Age and gender were not associated with the development of skin reactions. Conclusion: Our results showed similar development rates of skin reactions in both groups, except for the timing which was faster for enalapril.

Keywords

References

  1. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Smith RD. New perspectives in angiotensin system control. J Hum Hypertens 1993; 7 (Suppl 2): S19-S31.
  2. Powers B, Greene L, Balfe LM. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. J Manag Care Pharm 2011; 17 (8 Suppl): S1-14.
  3. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334(25): 1649-54.
  4. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 2008; 101(5): 495-9.
  5. Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007; 98(1): 57-63.
  6. Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Saf 1992; 7(1): 14-31.
  7. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004; 164(8): 910-3.
  8. Brouard M, Piguet V, Chavaz P, Borradori L. Schonlein-Henoch purpura associated with losartan treatment and presence of antineutrophil cytoplasmic antibodies of x specificity. Br J Dermatol 2001; 145(2): 362-3.
  9. Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev 2002; 10(6): 337-48.
  10. McCabe J, Stork C, Mailloux D, Su M. Penile angioedema associated with the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers. Am J Health Syst Pharm 2008; 65(5): 420-1.
  11. Rosenborg S. Cross reactivity between ACE inhibitors and angiotensin receptor blockers. Lakartidningen 2010; 107(7): 444. [In Swedish].
  12. Roskiewicz F, Andriamanana I, Gras-Champel V, Andrejak M, Massy ZA. Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers. Nephrol Ther 2007; 3(3): 89-95. [In French].
  13. Roten SV, Mainetti C, Donath R, Saurat JH. Enalapril-induced lichen planus-like eruption. J Am Acad Dermatol 1995; 32(2 Pt 1): 293-5.
  14. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165(14): 1637-42.
Journal of Isfahan Medical School
Volume 29, Issue 173 - Serial Number 173
November and December 2012
Pages 3040-3045

Files

History

  • Receive Date: 12 March 2012
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics